GlassScriptPhysician profile
Fang S Ko
NPI 1205060290
$36,300.06
in general payments reported to CMS, 2019-2025
20 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $168 · 2021: $655 · 2022: $27K · 2023: $5,983 · 2024: $657 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,250 · Food and Beverage: $2,189 · Travel and Lodging: $22.53 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,250.00 |
| Food and Beverage | $2,188.79 |
| Travel and Lodging | $22.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $32,454.71 | 2019-2024 | Cequa |
| Abbvie INC. | $880.90 | 2022-2025 | |
| Alcon Vision LLC | $719.72 | 2019-2025 | Rocklatan, Clareon, Unity |
| Horizon Therapeutics Plc | $358.41 | 2021-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $354.86 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $263.92 | 2019-2023 | |
| Allergan, INC. | $236.54 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $228.32 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $204.66 | 2024-2025 | Xdemvy |
| Rxsight INC | $193.50 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Amgen INC. | $123.02 | 2024 | Tepezza |
| Glaukos Corporation | $78.95 | 2021-2024 | Idose |
| New World Medical,INC. | $44.92 | 2021-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Thea Pharma INC. | $28.12 | 2022-2025 | Iyuzeh |
| Dompe US, INC. | $27.09 | 2025 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.36 | 2019-2020 | |
| Ivantis, INC | $20.95 | 2020 | |
| Kala Pharmaceuticals, INC. | $20.91 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $17.80 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.